Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Tumor type

Biliary Tract Cancer

OncoTree code BILIARY_TRACT · 2 articles

Clinical · Molecular biology

Upfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real-World Implementation and Clinical Outcomes

Hussung S, Roth M, Akhoundova D, et al.

Cancer medicine

This real-world study evaluated the implementation of upfront comprehensive genomic profiling (CGP) in 80 patients with advanced biliary tract cancer (BTC). Clinically actionable alterations were detected in 52.5% of cases—predominantly in IDH1, FGFR2, ERBB2, KRAS G12C, and BRAF—with anatomical enrichment of FGFR2 and IDH1 in intrahepatic cholangiocarcinoma. Matched targeted therapies were administered to 11 of the 42 actionable patients, yielding a significantly longer treatment duration compared with the preceding systemic line (p = 0.0391) and enabling secondary surgical resection in two patients. These findings confirm the clinical feasibility and value of upfront CGP in BTC while emphasizing the critical need to bridge the gap between biomarker identification and drug access.

Clinical · Molecular biology

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, et al.

Clinical cancer research

This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.